Medical treatment of Parkinson's disease: today and the future

被引：0
作者：
Gardian, G. [1 ]
Vecsei, L. [1 ]
机构：
[1] Univ Szeged, Dept Neurol, Fac Med, H-6725 Szeged, Hungary
来源：
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS | 2010年 / 48卷 / 10期
关键词：
Parkinson's disease; neuroprotection; kynurenine system; symptomatic therapy; ADENOSINE A(2A) RECEPTORS; KYNURENIC ACID; QUINOLINIC ACID; CLINICAL-EFFICACY; LEVODOPA; METABOLISM; PATHWAY; BRAIN; BLIND; NEUROPROTECTION;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Idiopathic Parkinson's disease (PD) is the only neurodegenerative disorder for which highly effective symptomatic therapy is available. Although levodopa continues to be the gold standard of symptomatic efficacy for treatment of the cardinal motor features, its chronic use is associated with potentially disabling motor complications. This review provides a survey of the medication that can currently be utilized for pharmacological management of the motor and non-motor symptoms of Parkinson's disease. Focus is placed on recent and evolving studies evaluating symptomatic and neuroprotective effects of such medication, and on how such studies may impact the future management of Parkinson's disease.
引用
收藏
页码：633 / 642
页数：10
相关论文
共 61 条
  • [1] A reassessment of risks and benefits of dopamine agonists in Parkinson's disease
    Antonini, Angelo
    Tolosa, Eduardo
    Mizuno, Yoshikuni
    Yamamoto, Mitsutoshi
    Poewe, Werner H.
    [J]. LANCET NEUROLOGY, 2009, 8 (10) : 929 - 937
  • [2] ADENOSINE A(2A) RECEPTOR MESSENGER-RNA IS EXPRESSED BY ENKEPHALIN CELLS BUT NOT BY SOMATOSTATIN CELLS IN RAT STRIATUM - A COEXPRESSION STUDY
    AUGOOD, SJ
    EMSON, PC
    [J]. MOLECULAR BRAIN RESEARCH, 1994, 22 (1-4): : 204 - 210
  • [3] Beal M.F., 2009, PARKINSONISM RELAT D, V15, P189
  • [4] Drug-induced fibrotic valvular heart disease
    Bhattacharyya, Sanjeev
    Schapira, Anthony H.
    Mikhailidis, Dimitri P.
    Davar, Joseph
    [J]. LANCET, 2009, 374 (9689) : 577 - 585
  • [5] Trapping channel block of NMDA-activated responses by amantadine and memantine
    Blanpied, TA
    Boeckman, FA
    Aizenman, E
    Johnson, JW
    [J]. JOURNAL OF NEUROPHYSIOLOGY, 1997, 77 (01) : 309 - 323
  • [6] Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias
    Calon, F
    Dridi, M
    Hornykiewicz, O
    Bédard, PJ
    Rajput, AH
    Di Paolo, T
    [J]. BRAIN, 2004, 127 : 1075 - 1084
  • [7] Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia
    Cenci, M. Angela
    [J]. TRENDS IN NEUROSCIENCES, 2007, 30 (05) : 236 - 243
  • [8] A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition
    Clarke, A
    Johnson, ES
    Mallard, N
    Corn, TH
    Johnston, A
    Boyce, M
    Warrington, S
    MacMahon, DG
    [J]. JOURNAL OF NEURAL TRANSMISSION, 2003, 110 (11) : 1257 - 1271
  • [9] Dezsi Livia, 2009, Expert Rev Clin Pharmacol, V2, P631, DOI 10.1586/ecp.09.47
  • [10] Diaz NL, 2009, EXPERT REV NEUROTHER, V9, P1781, DOI [10.1586/ern.09.117, 10.1586/ERN.09.117]
1234567